patients

Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies

Source Node:
Time Stamp: February 7, 2024 10:49 AM - Modified On: February 7, 2024 - Published By:
Source Cluster:
Republished By Plato

Legislation Puts Renewed Focus on Next-Generation NK Cell Therapies New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those considered for human cell management business licenses. The National Assembly passed the “Amendment to the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals” in a plenary session paving the way for certain next generation NK Cell Therapy companies to recognized as a licensed

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

HealthCare AI: The Unavoidable Revolution in Modern Medicine

Source Node:
Time Stamp: October 5, 2023 3:39 PM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

By Eric Greenberg www.linkedin.com/in/ericabg In the evolving landscape of medical technology, there's one force that stands head and shoulders above the rest, promising a seismic shift in the very ethos of healthcare delivery: Artificial Intelligence (AI). As a seasoned technology and banking analyst, it is my considered opinion that Healthcare AI isn't just a trend or a buzzword. It’s the very future of medicine, poised to reshape everything we know about patient care, disease diagnosis, and medical research. To begin with, the economic implications of integrating AI in healthcare are

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo

Source Node:
Time Stamp: October 5, 2023 11:22 AM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo Clinical trials, the linchpin of medical research, have long been riddled with inefficiencies, from patient recruitment bottlenecks to data management hurdles. As a technology and banking analyst, I've seen how digital solutions can overhaul entire sectors, offering improved productivity and streamlined processes. It's high time that clinical trials get a dose of such digital innovation, and there's a potent combination on the horizon: digital watermarking coupled with Artificial Intelligence (AI). At first glance, one might wonder: how can a technique often

Clinical Squared and PlatoHealth Join Forces to Revolutionize Healthcare with Advanced Data Orchestration Powered by AI.

Source Node:
Time Stamp: September 20, 2023 12:28 PM - Modified On: September 20, 2023 - Published By:
Source Cluster:
Republished By Plato

Washington DC, September 20th, 2023 — Clinical Squared (C2) and Platohealth.ai are delighted to announce a groundbreaking partnership that promises to reshape the healthcare landscape. Their collaboration brings together the healthcare expertise of C2 and the cutting-edge AI and machine learning capabilities of Plato.ai to create innovative solutions. [gallery columns="2" link="none" size="large" ids="2281765,2281767"] Clinical Squared, a leader in healthcare market expertise, data architecture, software development, consultation and implementation services, will lend its extensive industry knowledge to Plato.ai's platform. In turn, Plato.ai will provide advanced AI and machine learning mechanisms to

Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications

Source Node:
Time Stamp: September 20, 2023 8:36 AM - Modified On: September 20, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionary AVERSA™ Technology Sets New Standard for Opioid Patch Safety ORLANDO, FL / September 20, 2023 - Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance of a U.S. patent for its cutting-edge AVERSA™ Technology. This groundbreaking innovation, utilizing taste aversion, marks a paradigm shift in addressing the primary routes of abuse associated with opioid-based transdermal patches. The newly granted patent, numbered U.S. patent 11,759,431, titled "Abuse and Misuse Deterrent Transdermal Systems," significantly bolsters Nutriband's intellectual property protection in the United States. It covers

The Convergence of MedTech and Blockchain: Transforming Healthcare

Source Node:
Time Stamp: September 14, 2023 4:39 PM - Modified On: September 14, 2023 - Published By:
Source Cluster:
Republished By Plato

The healthcare industry has witnessed a remarkable transformation driven by technological advancements in recent years. One groundbreaking convergence is the fusion of Medical Technology (MedTech) and blockchain technology. This synergy has the potential to revolutionize healthcare by enhancing data security, interoperability, and patient-centric care. Enhanced Data Security: One of the foremost challenges in healthcare is ensuring the security and privacy of patient data. Medical records contain sensitive information that must be protected from unauthorized access and cyber threats. Blockchain technology offers a robust solution to this problem. Blockchain operates on

My Health Manifesto : Cracking The Code : Flying Solo

Source Node:
Time Stamp: September 11, 2023 12:37 PM - Modified On: September 11, 2023 - Published By:
Source Cluster:
Republished By Plato

Today when I Google "how long can a person live with my GFR 5% / kidney function the answer was "a few hours to a few weeks without dialysis." In a study with 8000+ patients 65+ with similar numbers; a month was the survival time. @68 (Stage 5 kidney failure is less than 15% /GFR; I'm not even anywhere on/near the chart) As I enter my Fourteenth/14th month; I am Defiantly hopeful. positive and optimistic that My Miracle will continue. #notmytimetodie #superoutlier While I challenge this death sentence I feel better and clearer